Slideshows Images Quizzes

Flunisolide Nasal Solution

Last reviewed on RxList: 12/30/2008
Flunisolide Nasal Solution Side Effects Center

Last reviewed on RxList 10/5/2015

Flunisolide nasal solution is an anti-inflammatory glucocorticosteroid used to manage the nasal symptoms of seasonal or perennial rhinitis. Flunisolide nasal solution is available in generic form. Common side effects of flunisolide nasal solution include aftertaste, nasal burning and stinging, nosebleed, dry nose, sore throat, cough, nausea, hoarseness, and sinusitis.

For adults, the recommended starting dose of flunisolide nasal solution is 2 sprays (58 mcg) in each nostril 2 times a day (total dose 232 mcg/day). For pediatric patients 6 to 14 years of age, the recommended starting dose is one spray (29 mcg) in each nostril 3 times a day (total dose 174 mcg/day) or 2 sprays (58 mcg) in each nostril 2 times a day (total dose 232 mcg/day). Flunisolide nasal solution may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, flunisolide nasal solution should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Our Flunisolide Nasal Solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Flunisolide Nasal Solution Professional Information

SIDE EFFECTS

The adverse events rates listed below are based on symptoms spontaneously reported in multidose controlled clinical trials in comparing flunisolide nasal solution (29 mcg per spray) and flunisolide nasal solution (flunisolide nasal spray .025%) (25 mcg per spray) for treatment of allergic rhinitis. In patients receiving flunisolide nasal solution (flunisolide nasal spray .025%) the most common adverse events were transient aftertaste (17%) and transient nasal burning and stinging (13%). These symptoms did not usually interfere with treatment.

Adverse Event Rates for Flunisolide Nasal Solution (flunisolide nasal spray .025%) (29 mcg per spray)

Incidence Greater than 1% (probably casually related)

Respiratory: Nasal burning/stinging (13%), epistaxis*, nasal dryness, pharyngitis, cough increased

Gastrointestinal: Nausea

Special Senses: Aftertaste (17%)

Incidence 1% or Less (probably casually related)

Respiratory: Hoarseness

Special Senses: Abnormal sense of smell

Incidence 1% or Less (casual relationship unknown)+

Respiratory: Sinusitis

Adverse Event Rates for Flunisolide Nasal Solution (flunisolide nasal spray .025%) (25 mcg per spray)

Incidence Greater than 1% (probably casually related)

Respiratory: Nasal burning/stinging (44%), epistaxis*, nasal dryness*, pharyngitis*, cough increased

Gastrointestinal: Nausea

Special Senses: Aftertaste (8%)

Incidence 1% or Less (probably casually related)

Respiratory: Hoarseness, nasal ulcer

Incidence 1% or Less (casual relationship unknown)+

Respiratory: Sinusitis

* Incidence of reported reaction between 3% and 9%. Those reactions occurring in less than 3% of the patients are unmarked.
+ Reactions occurred under circumstances where the casual relationship has not been clearly established; they are presented as alerting information for physicians.

Cases of growth suppression have been reported for intranasal corticosteroids (including flunisolide nasal solution) (see PRECAUTIONS, Pediatric Use section).

Read the entire FDA prescribing information for Flunisolide Nasal Solution (Flunisolide Nasal Spray .025%)

Related Resources for Flunisolide Nasal Solution

© Flunisolide Nasal Solution Patient Information is supplied by Cerner Multum, Inc. and Flunisolide Nasal Solution Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors